Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,427 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Ketone Metabolism in Type 1 Diabetes

NCT02471040
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Beta-hydroxybutyrate, Normal Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

NCT04026321
View directory record Official record
Conditions
Solid Tumor Refractory to Standard Therapy
Interventions
SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%
Drug
Lead sponsor
Livzon Pharmaceutical Group Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

NCT01100255
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine infusion, Saline
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia

NCT00894517
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years to 70 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT03397121
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Mission Viejo, California • Newport Beach, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 17, 2026, 2:18 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 2:18 AM EDT
Withdrawn Phase 1 Interventional

Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity

NCT00942838
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma
Interventions
Cisplatin, Whole Abdomen Radiotherapy
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

NCT04845178
View directory record Official record
Conditions
Migraine
Interventions
ABP-450, Placebo
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
View directory record Official record
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

NCT02889848
View directory record Official record
Conditions
Fibroids, Uterine, Leiomyoma
Interventions
Saline, EN3835
Other · Drug
Lead sponsor
Advance Biofactures Corporation
Industry
Eligibility
35 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Study Assessing Pain Relief After Replacement of the Knee

NCT06799845
View directory record Official record
Conditions
Total Knee Arthroplasty (Postoperative Pain)
Interventions
ATX101, bupivacaine hydrochloride, saline placebo
Drug
Lead sponsor
Allay Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Little Rock, Arkansas • Tamarac, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 17, 2026, 2:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of an Inactivated Yellow Fever Virus Vaccine

NCT05172544
View directory record Official record
Conditions
Yellow Fever
Interventions
HydroVax-002 YFV, Placebo
Biological · Other
Lead sponsor
Najit Technologies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incidence of Headache Following an Unintentional Dural Puncture

NCT01977898
View directory record Official record
Conditions
Postdural Puncture Headache, Post-Lumbar Puncture Headache, Cerebrospinal Fluid Leaks
Interventions
Morphine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 17, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 17, 2026, 2:18 AM EDT